Orelabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.

ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity.

Rilzabrutinib is a BTK inhibitor.

BMS-986195 is a potent, covalent, irreversible BTK inhibitor with IC50 value of 0.1nM.

Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.

BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.

BTK IN-1 is a potent BTK inhibitor, with an IC50 of <100 nM.

GDC-0853 is a potent and orally BTK inhibitor.

ONO-4059 is a highly selective BTK inhibitor with IC50 of 2.2 nM.

Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.

BMS-986142 is a potent, selective, reversible BTK inhibitor. BMS-986142 shows BTK IC50 = 0.5nM and human WB IC50 = 90 nM.

Btk inhibitor 1 R-enantiomer is a Btk kinase inhibitor.

AVL-292 is a covalent and highly selective inhibitor of Btk with IC50 of 0.5 nM, exhibiting > 1400-fold selectivity over the other kinases assayed.